A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival.

Tomoaki Nagao,Gaku Oshikawa,Sho Ishida,Hiroki Akiyama,Yoshiko Umezawa,Ai Nogami,Takeshi Kurosu,Osamu Miura

A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival.

2015

Tomoaki Nagao
Gaku Oshikawa
Sho Ishida
Hiroki Akiyama
Yoshiko Umezawa
Ai Nogami
Takeshi Kurosu
Osamu Miura

A novel MYD88 mutation, L265RPP, in Waldenstrom macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival

Keywords:

Cancer research
Immunology
Bcl-xL
Cell
NF-κB
Signal transduction
Mutation
Downregulation and upregulation
NFKB1
Waldenstrom macroglobulinemia
Biology
Molecular biology
Myeloid Differentiation Factor 88

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations